27 min listen
"CDK4/6 Inhibitor Plus Hormonal Therapy Should Be First Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO 2019 Cov…
"CDK4/6 Inhibitor Plus Hormonal Therapy Should Be First Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO 2019 Cov…
ratings:
Length:
9 minutes
Released:
Oct 14, 2019
Format:
Podcast episode
Description
Dr. Dennis Slamon is professor of medicine and executive vice chair for research for the UCLA Department of Medicine. He also serves as director of clinical/translational research and director of the Revlon/UCLA Women's Cancer Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is probably best known for doing the laboratory and clinical research that led to the development of Herceptin, the first medicine to specifically treat HER2-positive breast cancer. Dr. Slamon has won numerous awards for his research. Earlier this month, he received the 2019 Lasker Award for clinical medical research for his groundbreaking work on Herceptin.
At the European Society for Medical Oncology 2019 Congress, he presented overall survival results from the MONALEESA-3 study, looking at using the CDK4/6 inhibitor Kisqali (chemical name: ribociclib) plus the hormonal therapy Faslodex (chemical name: fulvestrant) to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women.
Listen to the podcast to hear Dr. Slamon explain:
the background of the MONALEESA-3 study
how much adding Kisqali to Faslodex improved overall survival compared to Faslodex alone
treatment side effects seen in the study
what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer
At the European Society for Medical Oncology 2019 Congress, he presented overall survival results from the MONALEESA-3 study, looking at using the CDK4/6 inhibitor Kisqali (chemical name: ribociclib) plus the hormonal therapy Faslodex (chemical name: fulvestrant) to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women.
Listen to the podcast to hear Dr. Slamon explain:
the background of the MONALEESA-3 study
how much adding Kisqali to Faslodex improved overall survival compared to Faslodex alone
treatment side effects seen in the study
what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer
Released:
Oct 14, 2019
Format:
Podcast episode
Titles in the series (100)
April 2014 Research Highlights by Breastcancer.org Podcast